A familiar peptide name can conceal a material difference. A paper may examine a fragment, labelled derivative, different terminal form or mixture while a later summary discusses the unqualified name. Before transferring the result, check what molecule was actually used and which details remain unresolved.
Build a definition from the methods
Start with the materials section, supporting chemistry and any cited source of the reagent. Record the sequence or structural definition where available, the terminal groups, stereochemistry and any attached label or other modification.
NIH’s resource-authentication guidance recognises that key biological and chemical reagents can vary between laboratories or over time in ways that affect research data. Its authentication expectation is separate from simply obtaining a reagent from a supplier.NIH — Authentication of Key Biological and/or Chemical Resources (opens in a new tab)
| Detail | Question |
|---|---|
| Sequence | Is this the complete entity or a fragment? |
| Termini | Are the end groups specified? |
| Stereochemistry | Are any D residues or other configurations stated? |
| Attached groups | Is a label, lipid or other modification present? |
| Material context | Is this an isolated component, complex or mixture? |
The table is a comparison aid, not an instruction to infer missing chemistry. If the article gives only a name, the precise form may require another source before it can be established.
Keep a labelled reagent distinct from its unlabelled parent
In an original hypothetical paper, a fluorescently labelled derivative of Peptide Q is used to visualise binding. A later summary says that Peptide Q entered cells. The label is part of the tested material and should remain visible in the description.
The paper may contain a comparison showing that the labelled and unlabelled forms behave similarly for a particular assay. If so, identify exactly what was compared. Similarity in that assay does not automatically establish identical behaviour for every property.
If no such comparison is reported, describe the observed behaviour of the labelled derivative. Do not silently remove the qualifier to make the evidence apply to the parent molecule.
Separate molecular identity from the supplied preparation
A sequence match does not establish that two preparations have the same composition. Counterions, complexation, added components and the basis of stated concentration may still differ.
For a blend, locate which components and proportions were studied. Evidence from one isolated component does not directly become evidence for the full mixture, and a mixture’s result cannot automatically be assigned to one constituent.
Supplier and catalogue identifiers can help trace the material, but the relevant historical specification may differ from a current listing. A paper’s batch-specific data or supporting characterisation can be more informative than a present-day product name.
Keep identity verification separate from authentication of a particular supplier report. Reading a structure or mass result in a paper does not independently confirm the origin, handling or performance of a different vial.
Record a match, a difference or an unresolved field
A practical evidence table can give each relevant field one of three outcomes: documented match, documented difference or not established. This is clearer than one overall same-compound label that hides a mixture of known and unknown details.
For a documented difference, explain its relevance to the claim without inventing an effect. A terminal modification is a molecular difference; whether it changes the studied response requires evidence rather than an assumption in either direction.
For an unresolved field, keep the limitation in the summary and avoid filling it from common commercial practice. The most common marketed form need not be the form used in the experiment.
The result of this audit is a more precise evidence boundary: the paper studied this defined material under these conditions. Broader relevance can then be considered explicitly, with the molecular bridge visible to the reader.
Sources and further detail
- NIH — Authentication of Key Biological and/or Chemical Resources (opens in a new tab)
31 May 2017 notice read for reagent variability and authentication distinct from supplier provision. Not presented as current UK commercial requirements. The Peptide Q example and identity-audit fields are original.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.